- Oral presentation
- Open Access
PRECIS-2: a tool to improve the applicability of randomised controlled trials
© Loudon et al; licensee BioMed Central Ltd. 2013
- Published: 29 November 2013
- Randomise Control Trial
- Likert Scale
- Healthcare System
- Experienced Trialist
- Expert Panel
RCTs are considered the most rigorous design to evaluate the effectiveness of different interventions but have generalizability issues. Our tool, PRECIS, could help trialists consider the effects of their design decisions on the applicability of their results in clinical settings.
To produce an improved and validated version of PRECIS.
Phase 1 involved brainstorming and a two-round Delphi survey of authors who cited PRECIS. Phase 2 involved discussion of the Delphi results by experienced trialists and alternative versions of PRECIS-2 developed and user-tested. Phase 3 will evaluate the validity and reliability of the most promising PRECIS-2 candidate using a sample of 15-20 trials rated by 15 other trialists.
Brainstorming sessions identified the PRECIS presentation (a wheel), lack of a scoring system and domain weighting as issues for exploration in the Delphi process. Thirty four completed responses from 90 invitees were received in Round 1 of the Delphi; Round 2 involved 23 individuals (response rate 82%). 45% selected a 1-5 Likert scale, 56.5% wanted to use a table (to justify decisions) and a PRECIS wheel, 26% were in favour of weighting domains. Suggestions for extra domains included: recruitment process for participants and integration of the intervention into the healthcare system. An expert panel in Toronto used the Delphi suggestions to help create alternative versions of PRECIS-2 for user-testing in spring 2013.
PRECIS can be improved by the addition of a Likert scale and additional domains. We expect to have a validated PRECIS-2 by the beginning of 2014.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.